Although published in 2023, the MAINTAIN trial remains a key reference in the evolving management of HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitors.
In this randomized, placebo-controlled phase II study, switching endocrine therapy and continuing CDK4/6 inhibition with ribociclib led to a statistically significant improvement in progression-free survival compared to endocrine therapy alone (median PFS: 5.29 vs. 2.76 months; HR 0.57; P = .006).
These findings are particularly relevant in clinical practice today, as the field continues to evaluate optimal sequencing strategies after CDK4/6i progression.
Kalinsky et al., J Clin Oncol 2023
